Clinical trials
Metastatic Tumor clinical trials
Below are recruiting metastatic tumor clinical trials, each written for real people, not researchers. We’re tracking 587 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06713161Recruiting
New dye to spot breast cancer during surgery
This study tests a special dye that helps surgeons see breast cancer tissue and nearby lymph nodes more clearly during surgery. The goal is to make sure all cancer is removed while sparing healthy tissue.
Kunming, YunnanAges 18–75 - NCT06807502Recruiting
Blood test for breast cancer follow-up
This trial uses a simple blood test (ScreenCell device) to look for circulating tumor cells (CTCs) in women. It aims to see if CTCs help monitor breast cancer during follow-up, including for those with metastatic or newly diagnosed breast cancer, as well as healthy volunteers.
Neuilly-sur-SeineAges 18 years+ - NCT07410494RecruitingPhase 1/Phase 2
Personalized donor cell therapy for advanced solid tumors
This trial tests a personalized cell therapy (CAR-NK) using donor immune cells that are engineered to find and attack one or two markers on advanced solid tumors. It may be an option for people whose tumors have these specific markers and have exhausted other treatments.
Beijing, Beijing MunicipalityAges 8–85 - NCT06061705Recruiting
Finding markers in patients with head and neck cancer on immunotherapy
This trial looks for specific signs in your blood and tumor tissue that may show how well immunotherapy is working for recurrent or metastatic head and neck cancer. It aims to help doctors personalize treatment in the future.
ParisAges 18 years+ - NCT06170788RecruitingPhase 3
New Two-Drug Immunotherapy Combo vs. Standard Immunotherapy for Advanced Lung Cancer
This study compares a new combination of two immunotherapy drugs (sacituzumab tirumotecan plus pembrolizumab) versus pembrolizumab alone for people with advanced non-small cell lung cancer that has a high PD-L1 level (≥50%) and has not been treated yet. The goal is to see if the combination works better than the standard single immunotherapy.
Phoenix, ArizonaAges 18 years+ - NCT07529808RecruitingPhase 1/Phase 2
New Drug BHB810 for Advanced Stomach Cancer
This trial tests a new drug called BHB810 for gastric (stomach) and gastroesophageal junction cancer that has stopped responding to standard treatments or has no standard options available. The drug targets a protein called CDH17 found on cancer cells and may help slow or shrink the tumor.
Fairfax, VirginiaAges 18 years+ - NCT06683846RecruitingPhase 2
Ivonescimab for advanced rare tumors: a safety & early-efficacy study
This trial tests a drug called ivonescimab in people with advanced, rare tumor types that have spread (stage IV). The goal is to see if the drug is safe and whether it can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05755672Recruiting
Study biomarkers during curative-intent treatment for metastatic colon cancer
This study looks at biological markers (substances measured in the body) during treatment for metastatic colorectal cancer. It may help doctors better understand how treatment works, using patients who are treated with a goal of cure.
Lund, Skåne CountyAges 18–110 - NCT06338683RecruitingPhase 3
Olanzapine for advanced upper digestive and lung cancer survival
This study tests whether a medicine called olanzapine can improve survival in people with advanced cancers of the upper digestive system or lungs. Olanzapine may help with appetite and weight, which are common problems in these cancers.
Xining, QinghaiAges 18–80 - NCT03422302Recruiting
CPAP or breath-holding to reduce lung tumor motion
This study looks at whether using a CPAP breathing device or deep breath-holding can keep lung tumors from moving during targeted radiation. The goal is to improve safety and accuracy of stereotactic body radiation for lung cancer.
Houston, TexasAges 18 years+ - NCT06481813Recruiting
Lung Cancer Biobank Study for Newly Diagnosed Patients
This trial collects blood and tissue samples from people newly diagnosed with lung cancer (NSCLC or CPC) to study the disease over time. It helps researchers understand how different treatments affect the cancer and the body.
NantesAges 18 years+ - NCT04623502Recruiting
Study of kidney and bladder cancer metabolism during surgery
This study looks at how kidney and bladder (urothelial) tumors use fuel by taking samples during surgery or biopsy. It may help researchers learn what drives these cancers and guide better future treatments.
Dallas, TexasAges 18 years+ - NCT06600802Recruiting
Lu-PSMA treatment for advanced prostate cancer
This study tests a radioactive drug called Lu-PSMA-617 for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly to the tumor.
Clermont-FerrandAges 18 years+ - NCT07030569Recruiting
Predicting treatment response in metastatic breast cancer
This trial studies how well CT and PET scans can predict if a certain type of breast cancer will respond to a targeted treatment. It focuses on women who had a biopsy of the liver, lung, or chest lining after the cancer spread.
MilanAges Any age - NCT06171139Recruiting
Genetic counseling tool for Black men with prostate cancer
This study tests a new tool to help Black or African American men with prostate cancer understand genetic testing options. The goal is to improve counseling and decision-making about tumor genetic testing.
San Francisco, CaliforniaAges 18 years+ - NCT07145177RecruitingPhase 1
Lu177-PSMA with liver treatment for advanced prostate cancer
This trial tests a targeted radiation drug (Lu177-PSMA) combined with procedures that treat liver tumors directly (like ablation or radiation). It is for men with prostate cancer that has spread to the liver and is no longer responding to hormone therapy. The goal is to see if this combination works better together.
San Francisco, CaliforniaAges 18 years+ - NCT07067138Recruiting
Genetic testing to guide treatment for advanced breast cancer
This study looks at the genes in your cancer to find a treatment that might work better for you. It tests your tumor sample to match you with a drug that targets your cancer's specific weaknesses.
Bethesda, MarylandAges 18–120 - NCT07333066RecruitingPhase 3
Adding chemotherapy when first treatment response is limited
This trial tests whether adding a chemotherapy drug (docetaxel) to your current treatment (apalutamide) can help control prostate cancer that has spread and hasn't responded as well as hoped to apalutamide alone.
BayonneAges 18 years+ - NCT04104776RecruitingPhase 1/Phase 2
Test drug tulmimetostat for advanced cancers and lymphomas
This early-phase study tests tulmimetostat (DZR123) to shrink or control advanced solid tumors and certain lymphomas, and it may also test a combination in some prostate cancer groups. If you qualify, you’ll receive the study drug and be monitored closely, including blood tests and a request for tumor tissue to look for biomarkers.
Tampa, FloridaAges 18 years+ - NCT06298084RecruitingPhase 1/Phase 2
HER3-DXd for Advanced Breast Cancer After T-DXd
This study tests a new drug called HER3-DXd (alone or combined with other medicines) for people with advanced breast cancer that has already been treated with T-DXd (Enhertu) and then got worse. The goal is to see if the new drug can shrink tumors safely.
VillejuifAges 18 years+ - NCT07137416RecruitingPhase 1
Testing a new combination of cancer drugs for HER2-positive tumors and breast cancer
This trial tests the safety of combining two drugs, CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd), in people with HER2-positive solid tumors or certain types of breast cancer. If you have advanced cancer that hasn't responded to other treatments, this study may be an option.
Boston, MassachusettsAges 18 years+ - NCT05746325Recruiting
Tumor-pulse device for spinal cancer fluid spread
This trial tests whether Tumor Treating Fields (a non-surgical device that delivers treatment signals to cancer cells through the scalp/skin) can help people whose breast or lung cancer has spread into the fluid around the spine and brain. It focuses on people who have cancer cells found in spinal fluid and can safely use the device most of the day.
Jacksonville, FloridaAges 18 years+ - NCT05655780Recruiting
Irinotecan care guided by tumor genes and gut bacteria
This study looks at whether a patient’s tumor genetic makeup and gut bacteria activity can predict how well irinotecan-based treatment works and what side effects they might have. It may help personalize treatment to improve survival and quality of life for people with metastatic or unresectable colon cancer.
Maastricht, LimburgAges 18 years+ - NCT06484153RecruitingPhase 2
New drug combo for advanced colorectal cancer
This trial tests a new combination of three drugs—fruquintinib (a targeted therapy), pirfenidone (an anti-fibrotic drug), and an immunotherapy (anti-PD-1)—for people with advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this triple therapy can shrink tumors more effectively than current options.
Wuhan, HubeiAges 18–75
Hear when a new Metastatic Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic tumor?
- Yes. Clin2 currently lists 587 recruiting metastatic tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.